# Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

> **NCT03490760** · PHASE2 · TERMINATED · sponsor: **Baptist Health South Florida** · enrollment: 9 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03490760
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-09
- **Primary completion:** 2020-07-09
- **Final completion:** 2020-07-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Slow/poor enrollment
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03490760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03490760, "Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03490760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*